Democrats spar over healthcare in second round of presidential debates

In the second round of presidential debate of Democratic candidates, the hopefuls took on healthcare right away, debating Medicare-for-all proposals and a public option on stage. The arguments over healthcare “set a combative tone” for the rest of the debate and underscored the contentious national dialogue over the issue as a whole, the New York Times reported on July 30.

In addition, the debate highlighted a split among the Democratic party between those that support Medicare-for-all and those that do not.

“In the end, it was a battle between aspiration and pragmatism, a crystallization of the struggle between the party’s left and moderate factions,” the NY Times reported.

The healthcare debate comes at a time when the Affordable Care Act is facing is biggest challenge to date, after a federal judge declared the healthcare law unconstitutional in its entirety. The case is in the appeals process.

Among the Democrats, voters will have to decide on a candidate with a plan that either pushes the ACA forward or favors a new healthcare system entirely.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.